Please use this identifier to cite or link to this item:
Title: Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
Authors: Fernández-Caballero, Jose Ángel
Chueca, Natalia
Álvarez, Marta
Mérida, María Dolores
López, Josefa
Sánchez, José Antonio
Vinuesa, David
Martínez, María Ángeles
Hernández, José
García, Federico
Keywords: Dolutegravir;HIV;Integrase;Proviral DNA;Raltegravir
metadata.dc.subject.mesh: Adult
Anti-HIV Agents
CD4 Lymphocyte Count
DNA, Viral
Drug Resistance, Viral
HIV Infections
HIV Integrase
HIV Integrase Inhibitors
Heterocyclic Compounds, 3-Ring
Middle Aged
Pilot Projects
Raltegravir Potassium
Retrospective Studies
Salvage Therapy
Treatment Failure
Viral Load
Issue Date: 13-May-2016
Abstract: In our study, we have hypothesized that proviral DNA may show the history of mutations that emerged at previous failures to a Raltegravir containing regimen, in patients who are currently undetectable and candidates to simplification to a Dolutegravir containing regimen, in order to decide on once a day or twice a day dosing. We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1, all with a history of previous failure to a RAL containing regimen, that were successfully salvaged and had reached viral suppression. A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. After an average (IQR) time of 48 months (29-53) Integrase resistance mutations in proviral DNA were studied. All the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56), originating from Spain, and 4 were women. Median viral load (log) and CD4 count at the moment of the study on proviral DNA was of 1.3 log cp/ml (range 0-1.47) and 765.5 cells/μL (range; 436.75-1023.75). The median time (IQR) between previous failure to RAL and the study on proviral DNA was 48 (29-53) months. At Raltegravir failure, N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %). In proviral DNA, N155H was detected by population sequencing in three patients (42.8 %), and UDS demonstrated a 9.77 % relative abundance of N155H in the remaining patient. Sanger sequencing correctly identified all the secondary mutations. This is a pilot study that demonstrates the possibility of properly identifying N155H and some secondary mutations 29-53 months after failure.
metadata.dc.identifier.doi: 10.1186/s12879-016-1545-8
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC4866296.pdf401,01 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons